Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32828269
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
SARS-CoV-2 E protein is a potential ion channel that can be inhibited by
Gliclazide and Memantine
#MMPMID32828269
Singh Tomar PP
; Arkin IT
Biochem Biophys Res Commun
2020[Sep]; 530
(1
): 10-14
PMID32828269
show ga
COVID-19 is one of the most impactful pandemics in recorded history. As such, the
identification of inhibitory drugs against its etiological agent, SARS-CoV-2, is
of utmost importance, and in particular, repurposing may provide the fastest
route to curb the disease. As the first step in this route, we sought to identify
an attractive and viable target in the virus for pharmaceutical inhibition. Using
three bacteria-based assays that were tested on known viroporins, we demonstrate
that one of its essential components, the E protein, is a potential ion channel
and, therefore, is an excellent drug target. Channel activity was demonstrated
for E proteins in other coronaviruses, providing further emphasis on the
importance of this functionally to the virus' pathogenicity. The results of a
screening effort involving a repurposing drug library of ion channel blockers
yielded two compounds that inhibit the E protein: Gliclazide and Memantine. In
conclusion, as a route to curb viral virulence and abate COVID-19, we point to
the E protein of SARS-CoV-2 as an attractive drug target and identify off-label
compounds that inhibit it.
free
free
free
